Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I clinical trial of UCART-22 for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) in adult patients

Trial Profile

A Phase I clinical trial of UCART-22 for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) in adult patients

Planning
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2018

At a glance

  • Drugs UCART-22 (Primary)
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Jun 2018 According to a Cellectis media release, the US FDA has approved the Companys Investigational New Drug (IND) application to initiate a Phase 1 clinical trial. The company intends to initiate the study in H2 2018.
    • 09 May 2018 New trial record
    • 02 May 2018 According to a Cellectis media release,The clinical research will be led by Dr. Nitin Jain, Assistant Professor, and Prof. Hagop Kantarjian, Chairman in the Department of Leukemia and University Chair in Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top